Effect of pulmonary artery pressure‐guided therapy on heart failure readmission in a nationally representative cohort

• DOI: 10.1002/ehf2.13956
• Publication Date: 2022-05-13T09:59:06Z
• Authors: Yoshikazu Kishino; Toshiki Kuno; Aaqib H. Malik; Gregg M. Lanier; Daniel B. Sims; Ernesto Ruiz Duque; Alexandros Briaso...
• Keywords: Heart Failure; Male; Heart failure; Original Articles; Pulmonary Artery; Patient Readmission; 3. Good health; Cardiac Resynchronization Therapy; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Risk Factors; RC666-701; Pulmonary artery pressure‐guided therapy; Diseases of the circulatory (Cardiovascular) system; Humans; Cardiac Resynchronization Therapy Devices; CardioMEMS device; Readmission

Pulmonary artery pressure (PAP)-guided therapy in patients with heart failure (HF) using the CardioMEMS (CMM) device, an implantable PAP sensor, has been shown to reduce HF hospitalizations previous studies. We sought evaluate clinical benefit of CMM device regard 30, 90, and 180 day readmission rates real-world usage.